The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

ConsortiaTX Awarded Exclusive License for Food Allergy Microbial Therapy
Pharma & Human Health

ConsortiaTX Awarded Exclusive License for Food Allergy Microbial Therapy

OCT 24, 2018
Gut Bacteria May Play Role in Heart Attack Recovery
Animal Health

Gut Bacteria May Play Role in Heart Attack Recovery

OCT 24, 2018
Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn’s Disease
Finance

Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn’s Disease

OCT 23, 2018
Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development
Gastrointestinal

Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development

OCT 22, 2018
Symberix Announces Non-Dilutive Funding Support for Lead Programs
Finance

Symberix Announces Non-Dilutive Funding Support for Lead Programs

OCT 22, 2018
Wyss Institute Receives Grant from Cystic Fibrosis Foundation
Infectious Disease & AMR

Wyss Institute Receives Grant from Cystic Fibrosis Foundation

OCT 18, 2018
LNC Therapeutics Acquires Exclusive License for the Christensenella Patent from Cornell University
Pharma & Human Health

LNC Therapeutics Acquires Exclusive License for the Christensenella Patent from Cornell University

OCT 17, 2018
Microsoft Genomics Ventures into the Microbiome With Eagle Genomics
Animal Health

Microsoft Genomics Ventures into the Microbiome With Eagle Genomics

OCT 15, 2018
MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD
Clinical & Manufacturing

MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

OCT 15, 2018
Synthetic Biologics Prices $18,000,000 Public Offering
Finance

Synthetic Biologics Prices $18,000,000 Public Offering

OCT 12, 2018
Researchers Link Gut Bacteria to Heart Transplant Success or Failure
Pharma & Human Health

Researchers Link Gut Bacteria to Heart Transplant Success or Failure

OCT 11, 2018